The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: A randomized clinical trial

Experimental and Clinical Endocrinology and Diabetes

Volumn 123, Issue 5, 2015, Pages 289-295

  Esteghamati, A ^a   Azizi, R ^a   Ebadi, M ^a   Noshad, S ^a   Mousavizadeh, M ^a   Afarideh, M ^a   Nakhjavani, M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

adiponectin; inflammation; intercellular adhesion molecule; metformin; osteoprotegerin; pioglitazone

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; METFORMIN; OSTEOPROTEGERIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOQ PROTEIN, HUMAN; ANTIDIABETIC AGENT; AUTACOID; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; ICAM1 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; TNFRSF11B PROTEIN, HUMAN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; AGONISTS; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; FOLLOW UP; HYPERGLYCEMIA; IMMUNOLOGY; MIDDLE AGED; SEXUAL DEVELOPMENT;

ADIPONECTIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; MALE; METFORMIN; MIDDLE AGED; OSTEOPROTEGERIN; SEX CHARACTERISTICS; THIAZOLIDINEDIONES;

EID: 84930201781     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1396864     Document Type: Article

References (21)

1. Esteghamati A., Etemad K., Koohpayehzadeh J. et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005-2011. Diabetes Res Clin Pract: 2014; 103 319 327
2. Willerson J. T., Ridker P. M. Inflammation as a cardiovascular risk factor. Circulation: 2004; 109 II-2 II-10
3. Knudsen S., Foss C., Poulsen P. et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol: 2003; 149 39 42
4. Poston R. N., Haskard D. O., Coucher J. R. et al. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol: 1992; 14495 665 673
5. Willerson J. T. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis: 2002; 44 469 478
6. Shin J. Y., Shin Y. G., Chung C. H. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care: 2006; 29 1664 1666
7. Dhore C. R., Cleutjens J. P., Lutgens E. et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol: 2001; 21 1998 2003
8. Park J. S., Cho M. H., Nam J. S. et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol: 2011; 164 69 74
9. Yki-Järvinen H. Thiazolidinediones. New Engl J Med: 2004; 351 1106 1118
10. Sung B., Park S., Yu B. P. et al. Modulation of PPAR in aging, inflammation, and calorie restriction. J Gerontol A Biol Sci Med Sci: 2004; 59 997 1006
11. Isoda K., Young J. L., Zirlik A. et al. Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells. Arterioscler Thromb Vasc Biol: 2006; 26 611 617
12. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care: 2013; 36 S67 S74
13. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther: 2004; 26 177 190
14. Mirmiranpour H., Mousavizadeh M., Noshad S. et al. Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: A randomized clinical trial. J Diabetes Complications: 2013; 27 501 507
15. Olefsky J. M., Saltiel A. R. PPAR γ and the treatment of insulin resistance. Trends Endocrinol Metab: 2000; 11 362 368
16. Parulkar A. A., Pendergrass M. L., Granda-Ayala R. et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med: 2001; 134 61 71
17. [Anonymous] Consensus Development Conference on Insulin Resistance. Diabetes Care: 1998; 21 310 314
18. Haffner S. M., Greenberg A. S., Weston W. M. et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation: 2002; 106 679 684
19. Ridker P. M., Rifai N., Rose L. et al. Comparison of C-reactive potein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med: 2002; 347 1557 1565
20. Germeyer A., Jauckus J., Zorn M. et al. Metformin modulates IL-8, IL-1β, ICAM and IGFBP-1 expression in human endometrial stromal cells. Reprod Biomed Online: 2011; 22 327 334
21. Lihn A., Pedersen S. B., Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obesity Rev: 2005; 6 13 21